Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas E Witzig

Showing results (291-300 of 387) with videos related to

Pageof 39
Sort By:
American Journal of Hematology|April 12, 2014
Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cellsClive S Zent, Ronald P Taylor, Margaret A Lindorfer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2004
Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group StudyMegan M Garrity, Lawrence J Burgart, Michelle R Mahoney, et al.
Cancer Immunology, Immunotherapy : CII|July 2, 2013
CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosisBridget Charbonneau, Alice H Wang, Matthew J Maurer, et al.
The Oncologist|September 5, 2020
Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic LeukemiaPaul J Hampel, Timothy G Call, Kari G Rabe, et al.
Blood Cancer Journal|May 3, 2022
PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohortsSanjal H Desai, Levi Pederson, Betsy LaPlant, et al.
Blood Cancer Journal|March 27, 2021
Hypomagnesemia at the time of autologous stem cell transplantation for patients with diffuse large B-cell lymphoma is associated with an increased risk of failureJennifer J Gile, Camden L Lopez, Gordon J Ruan, et al.
Hematological Oncology|August 28, 2021
Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg typeRobert M Kraft, Stephen M Ansell, Jose C Villasboas, et al.
American Journal of Hematology|September 18, 2014
Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphomaThomas E Witzig, Matthew J Maurer, Thomas M Habermann, et al.
Iscience|June 1, 2023
Secreted ORF8 induces monocytic pro-inflammatory cytokines through NLRP3 pathways in patients with severe COVID-19Xiaosheng Wu, Michelle K Manske, Gordon J Ruan, et al.
Cancer Research|April 19, 2007
Proteomic analysis of waldenstrom macroglobulinemiaEvdoxia Hatjiharissi, Hai Ngo, Alexey A Leontovich, et al.
Pageof 39

Showing results (291-300 of 387) with videos related to

Sort By:
Pageof 39
American Journal of Hematology|April 12, 2014
Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cellsClive S Zent, Ronald P Taylor, Margaret A Lindorfer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2004
Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group StudyMegan M Garrity, Lawrence J Burgart, Michelle R Mahoney, et al.
Cancer Immunology, Immunotherapy : CII|July 2, 2013
CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosisBridget Charbonneau, Alice H Wang, Matthew J Maurer, et al.
The Oncologist|September 5, 2020
Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic LeukemiaPaul J Hampel, Timothy G Call, Kari G Rabe, et al.
Blood Cancer Journal|May 3, 2022
PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohortsSanjal H Desai, Levi Pederson, Betsy LaPlant, et al.
Blood Cancer Journal|March 27, 2021
Hypomagnesemia at the time of autologous stem cell transplantation for patients with diffuse large B-cell lymphoma is associated with an increased risk of failureJennifer J Gile, Camden L Lopez, Gordon J Ruan, et al.
Hematological Oncology|August 28, 2021
Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg typeRobert M Kraft, Stephen M Ansell, Jose C Villasboas, et al.
American Journal of Hematology|September 18, 2014
Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphomaThomas E Witzig, Matthew J Maurer, Thomas M Habermann, et al.
Iscience|June 1, 2023
Secreted ORF8 induces monocytic pro-inflammatory cytokines through NLRP3 pathways in patients with severe COVID-19Xiaosheng Wu, Michelle K Manske, Gordon J Ruan, et al.
Cancer Research|April 19, 2007
Proteomic analysis of waldenstrom macroglobulinemiaEvdoxia Hatjiharissi, Hai Ngo, Alexey A Leontovich, et al.
Pageof 39